title: Gastroesophageal reflux in the patients with asthma.
abstract: Thirty one patients with asthma (mean age was 44.4 10.7; range 18-63) were investigated for gastroesophageal reflux (GER). The patients were separated into two groups according to presence of reflux and/or nocturnal symptoms. 13 patients had one of the reflux and/or nocturnal asthma symptoms (Group 1), whereas 18 patients had none of them (Group 2). To assess GER patients underwent to scintigraphy with Tc99m. GER was determined 4 of 13 patients in group 1 (30,7 %) and 1 of 18 patients in group 2 (5,5 %). There was significant difference between the group 1 and group 2 in that respect (p < 0,001). The patients with established GER (5 patients) were given Omeprazole (a proton pomp inhibitor) 40 mg daily for 4 weeks following a 2 week placebo period. The patients recorded their daily and nocturnal symptoms of asthma, additional salbutamol use, morning and evening peak expiratory flow rates (PEFR) measurements in a daily chart during placebo and omeprazole treatment without changing their antiasthma treatment. Their PEFR, FEV1 values, daily and nocturnal symptoms and additional beta agonist use did not changed after omeprazole treatment except one. But their reflux symptoms (heartburn and regurgitation) were improved. As a consequence, we suggested that asthmatics which have some complaints of reflux should be searched for GER. Not the respiratory functions but GER symptoms can be improved w
authors.affiliation: Departments of Pulmonary Diseases, Osmangazi University School of Medicine Eskisehir, Turkey. emelharm@yahoo.com
authors.forename: E
authors.initials: E
authors.lastname: Harmanci
authors.forename: E
authors.initials: E
authors.lastname: Entok
authors.forename: M
authors.initials: M
authors.lastname: Metintas
authors.forename: E
authors.initials: E
authors.lastname: Vardareli
authors.forename: O
authors.initials: O
authors.lastname: Elbek
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000420:Albuterol / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D001249:Asthma / Q000150:complications* / Q000188:drug therapy; D001991:Bronchitis / Q000209:etiology / Q000517:prevention & control; D002940:Circadian Rhythm; D003864:Depression, Chemical; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D005541:Forced Expiratory Volume; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D010366:Peak Expiratory Flow Rate; D054328:Proton Pump Inhibitors; D011877:Radionuclide Imaging; D012636:Secretory Rate / Q000187:drug effects; D014136:Tracheitis / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D000420:Albuterol